- Home
- RIGL vs NLSP Comparison
RIGL vs NLSP Comparison
Compare RIGL & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- NLSP
- Stock Information
- Founded
- RIGL 1996
- NLSP 2015
- Country
- RIGL United States
- NLSP Switzerland
- Employees
- RIGL N/A
- NLSP N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- RIGL Health Care
- NLSP Health Care
- Exchange
- RIGL Nasdaq
- NLSP Nasdaq
- Market Cap
- RIGL 247.1M
- NLSP 243.8M
- IPO Year
- RIGL 2000
- NLSP 2021
- Fundamental
- Price
- RIGL $25.04
- NLSP $3.37
- Analyst Decision
- RIGL Buy
- NLSP
- Analyst Count
- RIGL 5
- NLSP 0
- Target Price
- RIGL $31.30
- NLSP N/A
- AVG Volume (30 Days)
- RIGL 288.9K
- NLSP 626.4K
- Earning Date
- RIGL 11-07-2024
- NLSP 11-29-2024
- Dividend Yield
- RIGL N/A
- NLSP N/A
- EPS Growth
- RIGL N/A
- NLSP N/A
- EPS
- RIGL 0.22
- NLSP N/A
- Revenue
- RIGL $157,374,000.00
- NLSP N/A
- Revenue This Year
- RIGL $38.26
- NLSP N/A
- Revenue Next Year
- RIGL $24.21
- NLSP N/A
- P/E Ratio
- RIGL $109.79
- NLSP N/A
- Revenue Growth
- RIGL 21.65
- NLSP N/A
- 52 Week Low
- RIGL $7.48
- NLSP $3.00
- 52 Week High
- RIGL $29.82
- NLSP $29.08
- Technical
- Relative Strength Index (RSI)
- RIGL 68.80
- NLSP 37.40
- Support Level
- RIGL $22.33
- NLSP $3.01
- Resistance Level
- RIGL $29.16
- NLSP $3.55
- Average True Range (ATR)
- RIGL 2.30
- NLSP 0.43
- MACD
- RIGL 0.41
- NLSP -0.01
- Stochastic Oscillator
- RIGL 69.96
- NLSP 20.98
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.